Overview
Insilico Medicine offers an AI-powered Pharma.AI platform for end-to-end drug discovery, including target identification via PandaOmics, generative molecule design with Chemistry42, and preclinical candidate nomination in 12-18 months. The platform targets diseases in oncology, fibrosis, immunology, neurology, and metabolism, with programs advancing to Phase 2 clinical trials, such as for idiopathic pulmonary fibrosis. It integrates multimodal data for druggable targets, with 95.7% having 3D structures and 86.5% classified as druggable.
Frequently asked questions
- What AI capabilities does Insilico Medicine provide for drug discovery?
- Pharma.AI includes PandaOmics for target prioritization across 38 diseases, Chemistry42 for generative molecule design, and TargetPro for multimodal target identification with high clinical success potential.
- What is the typical timeline for Insilico's preclinical drug candidates?
- From project initiation to preclinical candidate nomination averages 12-18 months, with 60-200 molecules synthesized per program, significantly faster than the traditional 3-6 years.
- In which therapeutic areas and geographies does Insilico operate?
- Focuses on oncology, fibrosis, immunology, neurology, and metabolism; clinical trials conducted in the U.S. and China, with a global pipeline of over 30 programs.